CJC-1295 DAC 5mg – Research Peptide

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed for extended activity in research settings. The addition of DAC allows the peptide to bind to albumin, prolonging its half-life compared to shorter-acting GHRH analogues.

In laboratory research contexts, CJC-1295 DAC is studied for its role in pituitary signaling pathways and endocrine regulatory mechanisms.

This 5mg lyophilized formulation is supplied at ≥99% purity and intended strictly for laboratory research purposes.

Key Features

• 5mg lyophilized CJC-1295 with DAC
• GHRH analogue with extended half-life
• Drug Affinity Complex (albumin binding)
• ≥99% purity
• Research use only
• Discreet Australian shipping

Mechanism Overview

CJC-1295 is structurally related to growth hormone-releasing hormone (GHRH). In research literature, it is described as interacting with GHRH receptors in pituitary models to influence downstream endocrine signaling pathways.

The inclusion of DAC enables albumin binding, which significantly extends the compound’s duration of action in experimental settings. This extended half-life differentiates CJC-1295 DAC from non-DAC (MOD GRF 1-29) variants, which are shorter acting.

Stability and Handling

CJC-1295 DAC is supplied in lyophilized (freeze-dried) form to preserve stability during storage and transport. Standard laboratory handling considerations include:

• Refrigerated storage following reconstitution
• Protection from direct light exposure
• Avoiding repeated temperature fluctuations

Cold-chain integrity is particularly important during Australian shipping conditions.

Research Use Only

CJC-1295 DAC is supplied strictly for laboratory research and educational purposes. It is not approved for therapeutic use and is not intended for human consumption.